A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chemotherapy Induced Anemia

Age range

20 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cancer patients

Exclusion criteria

a history of myocardial, cerebral or pulmonary infarction
severe hypertension beyond control by drugs

Treatment and study plan

Recombinant human erythropoietin

Drug

3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

Primary outcomes

The increase in Hb concentration

Time frame: Day 28th or later

Secondary outcomes

Changes in QOL scores

Time frame: 84 days

Sponsors and collaborators

Lead sponsor

Chugai Pharmaceutical

Industry

Registry information

Official study title

A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Important dates

Study start: 2004
Primary completion: 2004
Study completion: 2005
First posted: Sep 5, 2005
Registry last updated: Feb 2, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed